Meropenem Aurovit (Meropenem Anhydrous)

Meropenem inhibits bacterial cell wall synthesis by binding to penicillin‑binding proteins, preventing the cross‑linking of peptidoglycan strands. This disruption leads to loss of cell wall integrity and bacterial cell death. Its stability against many β‑lactamases expands its activity to resistant Gram‑negative and Gram‑positive pathogens.

The dosage of Meropenem Aurovit is determined by the prescribing clinician based on the type and severity of infection, patient weight, renal function, and local antimicrobial guidelines. Only a qualified healthcare professional should set the appropriate dose and infusion schedule.

Meropenem is classified as Pregnancy Category B, indicating that animal studies have not shown risk but there are no adequate human studies. It should be used during pregnancy only if clearly needed. Limited data are available for breastfeeding; the decision should be made by the prescriber weighing potential benefits and risks.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After verification of trade or institutional credentials, the sales team will provide pricing, availability, shipping details (including cold‑chain handling if required) and assist with import documentation.

Meropenem shares a similar spectrum with other carbapenems such as imipenem‑cilastatin and ertapenem, but it offers broader activity against Pseudomonas aeruginosa and certain resistant Enterobacteriaceae. It is less likely to cause seizures than imipenem and does not require co‑administration of a renal protective agent, making it a preferred option in many severe infections.

Meropenem Aurovit powder for infusion should be stored at 2‑8 °C in a refrigerator. Keep the vial in its original packaging, protect it from light, and avoid freezing. Once reconstituted, the solution should be used promptly according to the product label.

Meropenem Aurovit is supplied as a sterile powder that must be reconstituted with a compatible diluent and administered intravenously as an infusion. The infusion rate and duration are determined by the prescriber, typically over 15‑30 minutes, and may be adjusted for renal function or specific clinical scenarios.

Serious risks include the potential for seizures, especially in patients with renal impairment or pre‑existing central nervous system disorders, and severe hypersensitivity reactions such as anaphylaxis. Clostridioides difficile‑associated colitis is another important concern, requiring prompt recognition and management.

Meropenem Aurovit is contraindicated in patients with a known hypersensitivity to meropenem, other carbapenems, or any component of the formulation. Caution is also advised for individuals with a history of seizures, severe renal impairment, or those receiving concomitant medications that lower the seizure threshold.